Protective effect of curcumin, a Curcuma longa constituent, in early colonic inflammation in rats

Drug Development Research

Volumn 70, Issue 6, 2009, Pages 425-437

  Sánchez Calvo, Juan Manuel ^a   Villegas, Isabel ^a   Sánchez Fidalgo, Susana ^a   Camacho Barquero, Laura ^a   Talero, Elena ^a   Motilva, Virginia ^a   Alarcón De La Lastra, Catalina ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Colitis; Curcumin; Cyclo oxygenase (COX) 2; Inducible nitric oxide synthase (iNOS); Mitogen activated protein kinases (MAPKs); Neutrophils

Indexed keywords

ACETIC ACID; CURCUMIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOPEROXIDASE; NITRITE; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COLITIS; COLON MUCOSA; CONTROLLED STUDY; CURCUMA LONGA; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; TH1 CELL; WESTERN BLOTTING;

EID: 70349295367     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20319     Document Type: Article

References (57)

1. Alarcón de la Lastra C, Martin MJ, Motilva V. 1994. Antiulcer and gastroprotective effects of quercetin: a gross and histologic study. Pharmacology 48:56-62. (Pubitemid 23352664)
2. Ammon HPT, Wahl M. 1991. Pharmacology of Curcuma longa. Planta Med 57:1-7.
3. Assi K, Pillai R, Gómez-Muñoz A, Owen D, Salh B. 2006. The specific JNK inhibitor SP600125 targets tumour necrosis factor-α production and epithelial cell apoptosis in acute murine colitis. Immunology 118:112-121.
4. Atsumi T, Murakami Y, Shibuya K, Tonosaki K, Fujisawa S. 2005. Induction of cytotoxicity and apoptosis and inhibition of cyclooxygenase-2 gene expression, by curcumin and its analog, alpha-diisoeugenol. Anticancer Res 25:4029-4036. (Pubitemid 41665181)
5. Balasubramanyam M, Koteswari AA, Kumar RS, Monickaraj SF, Maheswari JU. 2003. Curcumin-induced inhibition of cellular reactive oxygen species generation. Novel therapeutic implications. J Biosci 28:715-721. (Pubitemid 37522778)
6. Bertevello PL, Logullo AF, Nonogaki S, Campos FM, Chiferi V, Alves CC, Torrinhas RS, Gama-Rodrigues JJ, Waitzberg DL. 2005. Immunohistochemical assessment of mucosal cytokine profile in acetic acid experimental colitis. Clinics 60:277-286.
7. Bobin-Dubigeon C, Collin X, Grimaud N, Robert JM, Le Baut G, Petit JY. 2001. Effects of tumour necrosis factor-α synthesis inhibitors on rat trinitrobenzene sulphonic acid-induced chronic colitis. Eur J Pharmacol 421:103-110. (Pubitemid 33082157)
8. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
9. Calabrese V, Butterfield DA, Stella AM. 2003. Nutritional antioxidants and the heme oxygenase pathway of stress tolerance, novel targets for neuroprotection in Alzheimer's disease. Ital J Biochem 52:177-181.
10. Camacho-Barquero L, Villegas I, Sánchez-Calvo JM, Talero E, Sánchez-Fidalgo S. 2007. Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int Immunol 7:333-342. (Pubitemid 46186172)
11. Cho JW, Park K, Kweon GR, Jang BC, Baek WK, Suh MH, Kim CW, Lee KS, Suh SI. 2005. Curcumin inhibits the expression of COX-2 in UVB-irradiated human keratinocytes (HaCaT) by inhibiting activation of AP-1: p38 MAP kinase and JNK as potential postream targets. Exp Mol Med 37:186-192. (Pubitemid 40992733)
12. Deguchi Y, Andoh A, Inatomi O, Yagi Y, Bamba S, Araki Y, Hata K, Tsujikawa T, Fujiyama Y. 2007. Curcumin prevents the development of dextran sulfate Sodium (DSS)-induced experimental colitis. Dig Dis Sci 52:2993-2998. (Pubitemid 47512496)
13. Dignass AU, Podolsky DK, Rachmilewicz D. 1995. NO chi generation by cultured small intestinal epithelial cells. Dig Dis Sci 40:1859-1865.
14. Elson CO, Sartor RB, Tennyson GS, Riddell RH. 1995. Experimental models of inflammatory bowel disease. Gastroenterology 109:1344-1367.
15. Fabia R, Willen R, Ar'Rajab A, Andersson R, Ahrén B, Bengmark S. 1992. Acetic acid-induced colitis in the rat: a reproducible experimental model for acute ulcerative colitis. Eur Surg Res 24:211-225.
16. Goel A, Boland CR, Chauhan DP. 2001. Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett 172:111-118. (Pubitemid 32889704)
17. Grisham MB, Beniot JN, Granger DN. 1990. Assessment of leukocyte involvement during ischemia and reperfusion of intestine. Methods Enzymol 186:729-742. (Pubitemid 20280020)
18. Hagar HH, El-Medany A, El-Eter E, Arafa M. 2007. Ameliorative effect of pyrrolidinedithiocarbamate on acetic acid-induced colitis in rats. Eur J Pharmacol 554:69-77. (Pubitemid 44822587)
19. Hollenbach E, Vieth M, Roessner A, Neumann M, Malfertheiner P, Naumann M. 2005. Inhibition of RICK/nuclear factor-kappaB and p38 signaling attenuates the inflammatory response in a murine model of Crohn disease. J Biol Chem 280:14981-14988. (Pubitemid 40562850)
20. Hommes D, van den Blink B, Plasse T, Bartelsman J, Xu C, Macpherson B, Tytgat G, Peppelenbosch M, Van Deventer S. 2002. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 122:7-14. (Pubitemid 34049188)
21. Itzkowitz SH. 2006. Molecular biology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol. Clin North Am 35:553-571. (Pubitemid 44307575)
22. Jagetia GC, Aggarwal BB. 2007. "Spicing up" of the immune system by curcumin. J Clin Immunol 27:19-35.
23. Jian YT, Mai GF, Wang JD, Zhang YL, Wang JD, Zhang YL, Luo RC, Fang YX. 2005. Preventive and therapeutic effects of NFkappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid. World J Gastroenterol 11:1747-1752.
24. Jiang H, Deng CS, Zhang M, Xia J. 2006. Curcumin-attenuated trinitrobenzene sulphonic acid induces chronic colitis by inhibiting expression of cyclooxygenase-2. World J Gastroenterol 12:3848-3853. (Pubitemid 44028396)
25. Johnson JJ, Mukhtar H. 2007. Curcumin for chemoprevention of colon cancer. Cancer Lett 255:170-181.
26. Kang G, Kong PJ, Yuh YJ, Lim SY, Yim SV. 2004. Curcumin suppresses lipopolysaccharide-induced cyclooxygenase-2 expression by inhibiting activator protein 1 and nuclear factor kappab bindings in BV2 microglial cells. J Pharmacol Sci 94:325-328. (Pubitemid 38470742)
27. Kim GY, Kim KH, Lee SH, Yoon MS, Lee HJ, Moon DO, Lee CM, Ahn SC, Park YC, Park YM. 2005. Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF-kappa B as potential targets. J Immunol 174:8116-8124.
28. Kurtovic J, Segal I. 2004. Recent advances in biological therapy for inflammatory bowel disease. Trop Gastroenterol 25:9-14.
29. Larmonier CB, Uno JK, Lee KM, Karrasch T, Laubitz D, Thurston R, Midura-Kiela MT, Ghishan FK, Sartor RB, Jobin C, Kiela PR. 2008. Limited effects of dietary curcumin on Th-1 driven colitis in IL-10 deficient mice suggest an IL-10 dependent mechanism of protection. Am J Physiol Gastrointest Liver Ph 295:G1079-G1091.
30. Leu TH, Maa MC. 2002. The molecular mechanisms for the antitumorigenic effect of curcumin. Curr Med Chem Anticancer Agents 2:357-370. (Pubitemid 34649879)
31. Maerten P, Geboes K, De Hertogh G, Shen C, Cadot P, Bullens DM, Van Assche G, Penninckx F, Rutgeerts P, Ceuppens JL. 2004. Functional expression of 4-1BB (CD137) in the inflammatory tissue in Crohn's disease. Clin Immunol 112:239-246. (Pubitemid 39078699)
32. Manning AM, Davis RJ. 2003. Targeting JNK for therapeutic benefit: from junk to gold? Nat Rev Drug Discov 2:554-565.
33. Martín AR, Villegas I, La Casa C, de la Lastra CA. 2004. Resveratrol, a polyphenol found in grapes, suppresses oxidative damage and stimulates apoptosis during early colonic inflammation in rats. Biochem Pharmacol 67:1399-1410. (Pubitemid 38315105)
34. Moon DO, Jin CY, Lee JD, Choi YH, Ahn SC, Lee CM, Jeong SC, Park YM, Kim GY. 2006. Curcumin decreases binding of Shigalike toxin-1B on human intestinal epithelial cell line HT29 stimulated with TNF-alpha and IL-1beta: suppression of p38, JNK and NF-kappaB p65 as potential targets. Biol Pharm Bull 29:1470-1475.
35. Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Thomas P, Dannenberg AJ. 2003. Curcumin prevents alcohol-induced liver disease in rats by inhibiting the expression of NF-kappa B-dependent genes. Am J Physiol Gastrointest Liver Physiol 284:G321-G327. (Pubitemid 36120138)
36. Negi PS, Jayaprakasha GK, Jagan Mohan Rao L, Sakariah KK. 1999. Antibacterial activity of turmeric oil: a byproduct from curcumin manufacture. J Agric Food Chem 47:4297-4300.
37. Plummer SM, Hill KA, Festing MF, Steward WP, Gescher AJ. 2001. Clinical development of leukocyte cyclooxygenase 2 activity as a systemic biomarker for cancer chemopreventive agents. Cancer Epidemiol Biomarkers Prev 10:1295-1299.
38. Ramsewak RS, DeWitt DL, Nair MG. 2000. Cytotoxicity, antioxidant and anti-inflammatory activities of curcumins I-III from Curcuma longa. Phytomedicine 7:303-308.
39. Salh B, Assi K, Templeman V, Parhar K, Owen D, Gómez-Muñoz A, Jacobson K. 2003. Curcumin attenuates DNB-induced murine colitis. Am J Physiol Gastrointest Liver Physiol 285:G235-G243. (Pubitemid 36736407)
40. Sánchez-Hidalgo M, Martín AR, Villegas I, de la Lastra CA. 2007. Rosiglitazone, a PPAR gamma ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats. Eur J Pharmacol 562:247-258. (Pubitemid 46560498)
41. Sandborn WJ, Yednock TA. 2003. Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am J Gastroenterol 98:2372-2382. (Pubitemid 37448744)
42. Schmidt C, Stallmach A. 2005. Etiology and pathogenesis of inflammatory bowel disease. Minerva Gastroenterol Dietol 51:127-145. (Pubitemid 44251906)
43. Shanahan F. 2001. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 120:622-635. (Pubitemid 32171636)
44. Shishodia S, Potdar P, Gairola CG, Aggarwal BB. 2003. Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NFkappaB activation through inhibition of IkappaBalpha kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis 24:1269-1279. (Pubitemid 36927068)
45. Sidhu GS, Mani H, Gaddipati JP, Singh AK, Seth P, Banaudha KK, Patnaik GK, Maheshwari RK. 1999. Curcumin enhances wound healing in streptozotocin induced diabetic rats and genetically diabetic mice. Wound Repair Regen 7:337-362. (Pubitemid 29523012)
46. Sugimoto K, Hanai H, Tozawa K, Aoshi T, Uchijima M, Nagata T, Koide Y. 2002. Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology 123:1912-1922. (Pubitemid 35408315)
47. Szanto I, Rubbia-Brandt L, Kiss P, Steger K, Banfi B. 2005. Expression of NOX1, a superoxide-generating NADPH oxidase, in colon cancer and inflammatory bowel disease. J Pathol 207:164-176. (Pubitemid 41404147)
48. Thompson-Chagoyan OC, Maldonado J, Gil A. 2005. Aetiology of inflammatory bowel disease (IBD): role of intestinal microbiota and gut-associated lymphoid tissue immune response. Clin Nutr 24:339-352. (Pubitemid 40668419)
49. Torres MI, Garcia-Martin M, Fernandez MI, Nieto N, Gil A, Ríos A. 1999. Experimental colitis induced by trinitrobenzenesulfonic acid: an ultrastructural and histochemical study. Dig Dis Sci 44:2523-2529. (Pubitemid 30027371)
50. Towbin H, Staehlin T, Gordon J. 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedures and some applications. Proc. Natl Acad Sci USA 76:4350-4354. (Pubitemid 9256559)
51. Ukil A, Maity S, Karmakar S, Datta N, Vedasiromoni JR, Das PK. 2003. Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol 139:209-218. (Pubitemid 36760353)
52. Venkataranganna MV, Rafiq M, Gopumadhavan S, Peer G, Babu UV, Mitra SK. 2007. NCB-02 (standardized Curcumin preparation) protects dinitrochlorobenzene- induced colitis through down-regulation of NFkappa-B and iNOS. World J Gastroenterol 13:1103-1107. (Pubitemid 46511014)
53. Villegas I, Alarcón de la Lastra C, Orjales A, La Casa C. 2003. A new flavonoid derivative, dosmalfate, attenuates the development of dextran sulphate sodium-induced colitis in mice. Int Immunopharmacol 3:1731-1741. (Pubitemid 37424023)
54. Waetzig GH, Seegert D, Rosenstiel P, Nikolaus S, Schreiber S. 2002. p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol 168:5342-5351. (Pubitemid 34496003)
55. Zhang F, Altorki NK, Mestre JR, Subbaramaiah K, Dannenberg AJ. 1999. Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis 20:445-451. (Pubitemid 29112633)
56. Zhang M, Deng C, Zheng J, Xia J, Sheng D. 2006. Curcumin inhibits trinitrobenzene sulphonic acid-induced colitis in rats by activation of peroxisome proliferator-activated receptor gamma. Int Immunopharmacol 6:1233-1242. (Pubitemid 43868183)
57. Zingarelli B, Hake PW, Burroughs TJ, Piraino G, O'connor M, Denenberg A. 2004. Activator protein-1 signalling pathway and apoptosis are modulated by poly (ADP-ribose) polymerase-1 in experimental colitis. Immunology 113:509-517.